Ads
related to: can colon cancer be detected by blood work explained diagram- Official Physician Site
Visit Site For A Treatment
Option For Metastatic Solid Tumors.
- Identifying Patients
Discover Patient Identification &
IHC Info. Will You Take Action?
- Dosing & Administration
Healthcare Professionals: See How
Your Patients May Receive Treatment
- Access Data & Results
View Data To See If A Treatment For
Metastatic Solid Tumors May Help.
- Mechanism Of Action
MOA For A Therapy In Multiple
Metastatic Solid Tumor Types.
- Request A Contact
Complete A Brief Form To Receive
Updates For A Treatment Option.
- Official Physician Site
Search results
Results From The WOW.Com Content Network
The Food and Drug Administration (FDA) has recently approved a blood test screening for colorectal cancer that has an over 83% success rate at detecting the presence of this form of cancer.
Another colon cancer screening method includes fecal occult blood tests that detect blood in the stool, which can be a warning sign of colon polyps or cancer. The FIT-DNA tests, such as Cologuard ...
In a study of more than 7,800 colon cancer patients, the new test from Guardant Health was able to detect the cancer with 83% sensitivity. “The idea of a blood-based test is something they’re ...
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum (parts of the large intestine). [5] Signs and symptoms may include blood in the stool , a change in bowel movements , weight loss, abdominal pain and fatigue. [ 9 ]
The M2-PK Test is a non-invasive screening method for the early detection of colorectal cancers and polyps which are known to be the precursors of colorectal cancer. The M2-PK Test which is used for stool analysis is available either as fully quantitative ELISA Test or as a rapid test that can be performed by any general practitioner without the need of a laboratory or any additional equipment.
In clinical trial data, published in The New England Journal of Medicine, Shield was found to have an 83.1% sensitivity rate, meaning 83.1% of patients with colorectal cancer detected by a ...